KPV vs LL-37
Both are natural human immune peptides with no controlled human trials, but they push in opposite directions: KPV dampens inflammatory signaling, LL-37 can drive it.
KPV
The anti-inflammatory tail of α-MSH, with real mechanism and real mouse data — but essentially no human trials.
Full KPV evidence reviewLL-37
Cathelicidin
Genuine innate-immunity biology, but its therapeutic use is preclinical — and the same peptide is implicated in driving inflammatory disease.
Full LL-37 evidence reviewSide by side
| KPV | LL-37 | |
|---|---|---|
| Marketed for | Inflammation, gut, wound healing | Infection, immunity, healing |
| Evidence grade | Preclinical / minimal | Preclinical / minimal |
| Family | Immune / metabolic | Immune / metabolic |
| Regulatory status | Not FDA-approved | Not FDA-approved |
| How it's obtained | Research-only | Research-only |
| Key human source | Dalmasso, Gastroenterology 2008 | Lande, Nature 2007 |
marks a row where the two differ. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
Our verdict
Neither has controlled human trials for the uses it is marketed for, and both are unapproved research-only material. KPV is the anti-inflammatory tripeptide tail of alpha-MSH, carried into cells by PepT1 and suppressing NF-kB from the inside, with reproducible mouse colitis data. LL-37 is the single human cathelicidin, with well-documented antimicrobial, immunomodulatory, and wound-healing activity in preclinical work, but it is genuinely double-edged: dysregulated LL-37 is implicated in rosacea, psoriasis, and lupus, so raising it is not obviously beneficial. On safety reasoning alone, LL-37 carries a documented mechanism for harm that KPV does not.
KPV fits if
KPV is the better fit for a reader focused on gut and inflammatory biology who wants the cleaner, one-directional mechanism.
LL-37 fits if
LL-37 is worth reading for the innate-immunity science itself, as long as the two-sided inflammatory risk is read alongside the claimed benefits.
Where to get it
Where to get peptide therapy
Clinician-led telehealth services that prescribe compounded peptides. The specific peptides offered vary by provider — confirm KPV availability before ordering.
